drugset / Trial / NCT01178827
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Oxybutynin | Small molecule | 5 mg | — |
| Subject | Trospium | Small molecule | 60 mg | — |